Surgical devices maker Theragenics is looking to add some employees overseas at it prepares to ramp up manufacturing at a new facility in Costa Rica, part of larger outsourcing plans that included cuts in the U.S.
Updated 6/24/2014 at 5:20 p.m. EST with comments from CareFusion.
The first prefilled syringe was launched in early 1980’s. Since then, more and more pharmaceutical companies have chosen to provide their drug in this delivery form and the market has grown to an estimated value of $2.5 billion in 2010 according to a report from the consulting firm Visiongain.
One challenge facing prefilled syringe manufacturers is maintaining the sterility of the drug during transfer and transportation. Compromise in the syringe integrity could lead to microbiological contamination of the drug, which may result in serious medical consequences for patients. Subsequent product recalls could tarnish the public image of pharmaceutical companies and lead to negative financial consequences.
According to a March 2011 survey conducted by the American College of Emergency Physicians, many doctors believe emergency rooms will become busier places, despite healthcare reform.
In the survey — an email questionnaire sent to 20,687 U.S. ER physicians to which 1,768 replied — more than 80 percent of emergency room physicians say the number of patients seen in ERs has either increased somewhat or significantly over the last year, a trend they expect to continue.
Sagentia is a company that thrives on complexity. Its business is built around helping both established and emerging technology companies avoid the uncertainties of innovation.
"We operate best where there is a complex scientific or technical problem that needs resolving as part of product development,” CEO Brent Hudson told MassDevice.
Hudson, who joined the research and development consulting firm in 2009, describes the services they offer as having a little ‘r’ and a big ‘D.’
Quintiles’ plans for $2.43 billion in bank financing have been put off indefinitely due to what the clinical research organization now describes as “recent unfavorable global credit market conditions.”
In postponing the financing, the Durham, N.C.-based CRO also said it would terminate its tender offer to pay cash to buy up to $525 million of 9.5 percent outstanding senior notes that are due in 2014.